Fosaprepitant | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Fosaprepitant
Health Canada Patents

PharmaCompass Sponsored Ads

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

Contact Supplier

FAMAR CDMO- From early development to commercial manufacturing.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Fosaprepitant

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

35 API Suppliers, 17 USDMF, 3 JDMF, 6 EU WC, 13 NDC API, 22 Listed Suppliers, $ API Reference Price

35 API Suppliers
17 USDMF
3 JDMF
6 EU WC
13 NDC API
22 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

4 Drugs in Development

4 Drugs in Development

INTERMEDIATES

3 Intermediate Suppliers

3 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

48 FDF Dossiers, 24 FDA Orange Book, 5 Europe, 1 Canada, 8 Australia, 1 South Africa, 9 Listed Dossiers

48 FDF Dossiers
24 FDA Orange Book
5 Europe
1 Canada
8 Australia
1 South Africa
9 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

POWDER;INTRAVENOUS - EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, POWDER;INTRAVENOUS - EQ 150MG BASE/VIAL

POWDER;INTRAVENOUS - EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
POWDER;INTRAVENOUS - EQ 150MG BASE/VIAL

RELATED EXCIPIENT COMPANIES

1 Nanjing Well Pharmaceutical, 3 Actylis, 1 BASF, 1 DFE Pharma, 3 Gangwal Chemicals, 7 Kerry, 1 Microlex e.U, 1 Nanjing Bold Chemical, 6 Seppic

1 Nanjing Well Pharmaceutical
3 Actylis
1 BASF
1 DFE Pharma
3 Gangwal Chemicals
7 Kerry
1 Microlex e.U
1 Nanjing Bold Chemical
6 Seppic

EXCIPIENTS BY APPLICATIONS

10 Solubilizers, 6 Parenteral, 5 Fillers, Diluents & Binders, 3 Emulsifying Agents, 3 Topical, 3 Co-Processed Excipients, 3 Direct Compression, 2 Thickeners and Stabilizers, 2 Film Formers & Plasticizers, 2 Surfactant & Foaming Agents, 1 API Stability Enhancers, 1 Granulation, 1 Rheology Modifiers

10 Solubilizers
6 Parenteral
5 Fillers, Diluents & Binders
3 Emulsifying Agents
3 Topical
3 Co-Processed Excipients
3 Direct Compression
2 Thickeners and Stabilizers
2 Film Formers & Plasticizers
2 Surfactant & Foaming Agents
1 API Stability Enhancers
1 Granulation
1 Rheology Modifiers

DIGITAL CONTENT

31 NEWS #PharmaBuzz

31 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 3 Finished Drug Prices

3 US Medicaid Prescriptions
3 Finished Drug Prices

MARKET PLACE

1 FDF Dossiers

1 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 US Patents, 2 US Exclusivities, 2 Health Canada Patents

2 US Patents
2 US Exclusivities
2 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 Others

2 Others

$ API Ref.Price (USD/KG) : 20,655 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

2 All

01 1Merck Canada Inc.

02 1Merck Frosst Canada Ltd

filter Patent Reset all filters

2 All

01 22183250

filter Product Reset all filters

2 All

01 2Fosaprepitant dimeglumine

filter Dosage Reset all filters

2 All

01 1Lyophilized powder

02 1Powder for solution

filter Exp Date Reset all filters

2 All

01 22015-02-28

Chemwerth Fosaprepitant

Product Main Page

01

Merck Frosst Canada Ltd

Fosaprepitant

The Generic Rx Session

Not Confirmed

Merck Frosst Canada Ltd

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2015-02-28

Date Granted : 2006-03-21

Fosaprepitant

Brand Name : EMEND IV

Patent Number : 2183250

Filing Date : 1995-02-28

Strength per Unit : 115 mg / vial

Dosage Form : Lyophilized powder

Human Or VET : Human

Route of Administration : Intravenous

Patent Expiration Date : 2015-02-28

Date Granted : 2006-03-21

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Merck Canada Inc.

Fosaprepitant

The Generic Rx Session

Not Confirmed

Merck Canada Inc.

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2015-02-28

Date Granted : 2006-03-21

Fosaprepitant

Brand Name : EMEND IV

Patent Number : 2183250

Filing Date : 1995-02-28

Strength per Unit : 150 mg

Dosage Form : Powder for solution

Human Or VET : Human

Route of Administration : Intravenous

Patent Expiration Date : 2015-02-28

Date Granted : 2006-03-21

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
ASK US!